Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xeris Biopharma Holdings Inc XERS

Healthcare Biotechnology
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia... see more

Recent & Breaking News (NDAQ:XERS)

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

Business Wire June 3, 2025

Xeris Announces Details for Analyst & Investor Day

Business Wire May 20, 2025

Xeris Biopharma Reports Record First Quarter 2025 Financial Results 

Business Wire May 8, 2025

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Business Wire May 1, 2025

Xeris Announces Changes to Its Board of Directors

Business Wire March 28, 2025

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx(TM) (glucagon) for Use as a Diagnostic Aid

Business Wire March 17, 2025

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Business Wire March 6, 2025

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Business Wire February 27, 2025

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Business Wire February 24, 2025

Xeris to Participate in Upcoming Investor Conferences

Business Wire February 5, 2025

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

PR Newswire January 21, 2025

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Business Wire January 10, 2025

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 6, 2025

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Business Wire November 26, 2024

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Business Wire November 8, 2024

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Business Wire October 31, 2024

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 4, 2024

Xeris to Participate in Upcoming Investor Conferences

Business Wire August 22, 2024

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Business Wire August 8, 2024

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Business Wire July 25, 2024